Kornimate/medical-research-clean huggingface dataset:
recovery of cardiovascular function with epidural stimulation after human spinal cord injury

Conditions: Spinal Cord Injury

Summary: we propose to demonstrate that epidural stimulation (es) can be used to recover significant levels of autonomic control of cardiovascular and respiratory function as well as the ability to voluntarily control leg movements below the injury level. this intervention would provide an immediate therapeutic alternative to individuals who now have no recourse for treatment.

we will enroll 4 research participants who have sustained a motor complete sci to participate in the proposed experiments. participants will be screened for eligibility, followed by 80 days of usual care, epidural implantation, 80 days of cardiovascular epidural stimulation training, 80 days of voluntary movement (vm) epidural stimulation training and finally 80 days of stand epidural stimulation training. these interventions are done in sequential order, however they are cumulative. in between each intervention, participants will undergo motor and cardiovascular experiments and assessments.

Eligibility criteria:
1. non-progressive sci with complete motor paralysis above t1; american spinal injury association impairment scale (ais) a, b or c; 2. 21 - 70 years of age; 3. greater than 2 years post injury; 4. stable medical condition; 5. unable to voluntarily move all single joints of the legs; 6. cardiovascular dysfunction including presence of persistent resting blood pressures and/or symptoms of autonomic dysreflexia and/or orthostatic hypotension; and 7. respiratory dysfunction including at least 15% deficit in predicted pulmonary function outcomes; exclusion criteria: 1. ventilator dependent; 2. painful musculoskeletal dysfunction, unhealed fracture, contracture, or pressure sore that might interfere with training; 3. clinically significant depression or ongoing drug abuse; 4. cardiovascular, respiratory, bladder, or renal disease unrelated to sci; 5. severe anemia (hgb\<8 g/dl) or hypovelemia; and 6. hiv or aids related illness.

Keywords: epidural stimulation
the safety, pharmacokinetic profile and efficacy of raltegravir in hiv-infected patients at least 60 years of age

Conditions: HIV

Summary: this is a phase iv, open label, prospective, one phase pharmacokinetic and observational study. twenty hiv-1 infected subjects will be recruited, subjects will switch antiretroviral therapy to: * tenofovir/emtricitabine 245/200 mg daily (truvada™) plus * raltegravir 400 mg twice daily on day 28, all subjects will attend for an intensive 24 hour pharmacokinetic visit.

this is a phase iv, open label, prospective, one phase pharmacokinetic and observational study. twenty hiv-1 infected subjects will be recruited. eligible subjects will currently be receiving stable antiretroviral therapy with undetectable plasma hiv rna and have no evidence of previous hiv- resistance mutations on genotypic resistance testing. at baseline, subjects will switch antiretroviral therapy to: * tenofovir/emtricitabine 245/200 mg daily (truvada™) plus * raltegravir 400 mg twice daily on day 28, all subjects will attend for an intensive 24 hour pharmacokinetic visit. follow up over 6 months, subjects will attend on days 14, 90 and 180 for follow up visits that will include standard safety parameters. assessment of cardiac biomarkers at baseline and on days 90 and 180 and assessment of neurocognitive function at screening, baseline and on day 180 will also be undertaken. following completion of this study, subjects will recommence their usual antiretroviral treatment regimen and attend for a study follow up visit.

Eligibility criteria:
inclusion criteria: 1. hiv-1 infected males or females 2. 60 years of age or greater\* 3. signed informed consent 4. willing to switch therapy as per study protocol 5. no previous exposure to raltegravir or hiv-1 integrase inhibitors 6. plasma hiv rna \< 50 copies/ml at screening and on at least one other occasion over the last 3 months 7. currently receiving a stable antiretroviral regimen with no antiretroviral drug switches for at least 3 months 8. no previous clinically-significant resistance documented on hiv-1 genotypic resistance 9. subjects in good health upon medical history, physical exam, and laboratory testing 10. bmi above or equal to 18 and below 32 11. male subjects who are heterosexually active must use two forms of barrier contraception (e.g., condom with spermicide) during heterosexual intercourse, from screening through completion of the study. 12. have local screening laboratory results (haematology and chemistry that fall within the normal range of the central laboratory's reference ranges unless the results have been determined by the investigator to have no clinical significance \* 50% of total enrolled cohort will be 65 years of age or over. subsequent to 10 subjects aged between 60 and 64 recruited, only subjects aged 65 or over will be eligible. exclusion criteria: 1. current alcohol abuse or drug dependence 2. positive urine drug of abuse screening 3. active opportunistic infection or significant co-morbidities 4. current disallowed concomitant medication

Keywords: hiv pharmatokinetic 60 years old raltegravir
prokinetics and body surface gastric mapping in dyspeptic patients: baseline and treatment effects

Conditions: Gastroparesis; Functional Dyspepsia

Summary: functional dyspepsia and gastroparesis are common stomach disorders with symptoms like early satiety, nausea, and abdominal pain, and are often evaluated with gastric emptying tests, although the correlation with symptoms is weak. prokinetic agents (e.g., metoclopramide, erythromycin) and symptom modulators (e.g., nortriptyline, mirtazapine) are commonly used, but selecting the right medication can be difficult, as it's often based on symptoms rather than the underlying gastric issues. body surface gastric mapping (bsgm) using the gastric alimetry device is a novel, non-invasive tool to assess gastric myoelectrical activity and symptoms. this study aims to perform two bsgm recordings-one before and one after medical therapy-to understand how medications affect gastric function and identify baseline bsgm factors that could predict responses to treatment, potentially guiding tailored therapies based on individual gastric dysfunction.


Eligibility criteria:
inclusion criteria: * patients 18 years of age and older * diagnosis of gastroparesis and/or functional dyspepsia * being prescribed a prokinetic agent or symptom modulator for their clinical care * able to undergo bsgm recording both before and during treatment * able to give informed consent for undergoing a baseline bsgm recording and an additional recording while on treatment exclusion criteria: * under 18 years of age * prior surgery on esophagus, stomach (appendectomy and cholecystectomy are allowed) * history of skin allergies or a history of extreme sensitivity to cosmetics or lotions * pregnant women * no vulnerable groups such as prisoners, individuals with known cognitive impairment, or institutionalized individuals be involved

Keywords: gastroparesis functional dyspepsia gastric motility body surface gastric mapping
clavipectoral block versus interscalene block for postoperative analgesia in midshaft clavicular surgery

Conditions: Post Operative Pain

Summary: the aim of this study is to compare between (isbpb) and (cpb) as postoperative analgesic technique following midshaft clavicular fracture open reduction and internal fixation surgeries.

the aim of this study is to compare between (isbpb) and (cpb) as postoperative analgesic technique following midshaft clavicular fracture open reduction and internal fixation surgeries. preoperative full precise medical history will be taken from patients. routine investigations will be done to all patients including ecg and laboratory investigations as cbc, ast, alt, inr, pt and ptt. demographic data as age and weight will be recorded. all patients will be consented for every anesthetic and surgical procedure to be done. for all patients, on arrival to the operating room, ecg, heart rate (hr), non-invasive blood pressure, and pulse oximetry will be monitored. patients will receive 0.03 mg/kg of iv midazolam as anxiolytic and 3 l/ min nasal oxygen. then, in supine position, the diaphragmatic excursion measurement will be performed on the hemidiaphragm at the same side of the study block. excursion amplitude will be defined as the craniocaudal perpendicular distance from the minimum to the maximum point of diaphragm excursion. diaphragmatic excursion measurements will be performed before induction of general anesthesia and performing the block technique and at 3 hours after the block or 1 hour after recovery from anesthesia if the surgery lasted more than 2 hours. after that, induction of ga will be performed by injecting intravenous (iv) 1 mcg/kg fentanyl, 2 mg/kg propofol and 0.5 mg/kg atracurium. then, the patients will receive one of the study blocks as following: group a: this group will receive ultrasound-guided clavipectoral fascia plane block. group b: this group will receive ultrasound-guided interscalene plexus block.

Eligibility criteria:
inclusion criteria: * patients aged from 21 to 60 years. * american society of anesthesiologists (asa) class i and ii status. * of both sexes. * patients undergoing elective midshaft clavicle fracture open reduction and internal fixation surgery. exclusion criteria: * patient refusal. * american society of anesthesiologists (asa) class lli and iv status. * patients with bleeding disorders. * a history of relevant drug allergy to any of the used drugs. * alcohol or drug abuse and opioid dependence. * pregnant female patients. * patients with bmi above 30 kg/m2. * patients with infection at site of the fracture or the block procedure. * patients with reduced pulmonary functions due to chronic obstructive pulmonary disease (copd), uncontrolled asthma, pneumothorax or pleural effusion.
stroke survival in municipalities: impact of geographic proximity to first- and second-degree relatives

Conditions: Stroke

Summary: our key objective will be to investigate if geographic proximity to first- and second-degree relatives has an influence on post-acute stroke survival and use of health and social services. we will also model and map spatial variation in stroke and cardiovascular disease (cvd) incidence and mortality and see if some of the variation is due to spatial clustering of familial risk. the study will use innovative approaches to large-scale registry and survey data and statistical analysis on the full norwegian population. we will integrate multigenerational and geographical information. this will enable us to assess key determinants on stroke survival and use of health and social care at municipality level.


Eligibility criteria:
inclusion criteria: * norwegian citizens aged 45 and above 1.1.1994 - 31.12. 2009 and had stroke events * those who attend a cardiovascular health survey who later developed stroke. * all norwegians born in the period 1 january 1940 to 31 december 1959 who survived to 1991 * norwegian citizens aged 45 and above 1.1.2016 and had stroke events exclusion criteria: -

Keywords: stroke post-acute stroke geographical proximity family relatives survival analysis
clinical outcomes of three different percutaneous revascularization strategies for the treatment of lifestyle limiting claudication: a retrospective analysis

Conditions: Peripheral Artery Disease

Summary: to determine the effect of three different percutaneous revascularization strategies (balloon cryoplasty vs. stent placement vs. atherectomy) in the treatment of lifestyle limiting lower extremity claudication

endovascular revascularization of the superficial femoral artery (sfa) has become one of the most commonly performed endovascular procedures.the ability to offer the patient an alternative to surgical revascularization, limited by significant morbidity and mortality, with a same-day outpatient percutaneous procedure underlies the popularity of the endovascular approach. although surgical bypass of the sfa remains the gold standard for revascularization, it is associated with significant morbidity and mortality.comparative data between cryoplasty, angioplasty or stenting of the sfa will ultimately be required to provide more robust evidence of the efficacy of each mode of therapy.this registry is designed to determine the efficacy of three different percutaneous revascularization strategies (cryoplasty vs. stent placement vs. atherectomy) in the treatment of lifestyle limiting lower extremity claudication.

Eligibility criteria:
inclusion criteria: * patients with superficial femoral artery disease as assessed by angiography

Keywords: pad peripheral artery disease pvd peripheral vascular disease leg blockage angioplasty stent claudication
trial of a culturally-appropriate weight loss intervention for overweight latino children

Conditions: Overweight

Summary: this project aims to conduct a unique, community-based intervention consisting of a randomized trial of a culturally-appropriate weight loss intervention for overweight latino children in milwaukee. the intervention promotes lifestyle changes through a low weight loss regimen, one or more physical activities ranging from soccer to hip-hop dance, and dietary counseling including cooking classes for parents. in addition to weight reduction for overweight latino children, the project has the potential to reduce missed school days and improve self-esteem and quality of life.


Eligibility criteria:
inclusion criteria: * children must be of latino descent * at risk for becoming overweight or is overweight * 6-17 years old. exclusion criteria: * age \> 17 years old * not overweight or at risk for becoming overweight * non-latino ethnicity/race.
the durability of response and persistence of resistance to abbvie's 2 direct-acting antiviral agent (2d) therapy in japanese subjects

Conditions: Hepatitis C Virus

Summary: this study seeks to assess the durability of response and persistence of resistance to ombitasvir/ paritaprevir/ritonavir in japanese participants who enrolled in a phase 2 or 3 clinical study with these agents for the treatment of chronic hepatitis c.


Eligibility criteria:
inclusion criteria: * participants treated in study m12-536 or m13-004 with the 2d regimen (ombitasvir/ paritaprevir/ ritonavir) and completed 48 weeks of follow-up, regardless of svr achievement. * participants who agree to sign the informed consent exclusion criteria: * participants treated with a direct-acting antiviral agent (daa) immediately after study m12-536 or m13-004.

Keywords: hepatitis c follow-up observation japanese
determinants of onset and progression of copd in young adults

Conditions: COPD

Summary: copd (chronic obstructive pulmonary disease) is a public health problem due to its impact in the patient's quality of life, high prevalence, growing incidence and socioeconomic implication. copd natural history and first stages determinants are unknown. knowing them will help to understand the natural history of the disease and to design interventions that can modify the prognosis of the disease. study objectives: (1) to characterize an early copd population from a multidimensional point of view including demographic, social, family and clinical data, lung function, exercise capacity, image, microbiology, quality of life, exacerbations, comorbidities and blood and sputum biomarkers. (2) to compare this patients with smoking subjects, with normal lung function, matched by age, sex and site. (3) to create an early copd cohort to be followed in the future to understand the complete natural history of the disease. methods: design: multicenter cross-sectional study that will allow establishing a well-characterized cohort of early copd patients for later follow-up. recruitment will be done in primary care settings. subjects: smokers (\> 10 packs year) between 35-50 years old with a spirometry (normal or obstructive) done in the last year. diagnosis of copd will be based on the smoking history and a postbronchodilator test fev1(forced expiratory volume in the first second) / fvc(forced vital capacity) \< 70%. age, sex and site matched 'healthy' smoker controls will be compared with the copd cases. variables that will be collected in the reference hospitals are: health questionnaires, lung function test, exercise capacity, blood and sputum samples, and low dose ct-scan. statistical analysis: early copd patient's characteristics will be described and then, will be compared, with control subjects through a conditional multiple logistic regression analysis.


Eligibility criteria:
\*\*inclusion criteria: copd case: * subjects between 35 and 50 years * post-bronchodilator spirometry with fev1/fvc \<70% * smoker or ex-smoker with total cumulative exposure \> 10 pack-years smoking control: * subjects between 35 and 50 years * post-bronchodilator spirometry with fev1/fvc \>=70% * smoker or ex-smoker with total cumulative exposure\> 10 pack-years * exclusion criteria: for cases: * chronic inflammatory diseases including autoimmune diseases under treatment. * hiv * active cancer * cystic or saccular bronchiectasis * conditions that may interfere with follow-up: frequent change of residence, psychiatric disorders, dementia... for controls: * chronic inflammatory diseases including autoimmune diseases under treatment * hiv * active cancer * chronic respiratory diseases: * active tuberculosis * interstitial lung diseases * cystic or saccular bronchiectasis * ever diagnosed asthma * deficit of alpha1-antitrypsin * conditions that may interfere with follow-up: frequent change of residence, psychiatric disorders, dementia ...
reducing alcohol use and sexual dysfunction in survivors of sexual trauma

Conditions: Alcohol Use, Unspecified; Sexual Dysfunction; Sexual Assault

Summary: the goal of this clinical trial is to develop and evaluate the preliminary efficacy of an intervention to address alcohol use, sexual distress, and sexual assault risk among college women with a history of sexual victimization. the main questions it aims to answer are: 1) what is the feasibility of the recruitment method, research design, interventionist training methods, and delivery of the intervention; 2) does the intervention, relatively to control, the 2- and 6-month follow-up produces reductions in the quantity/frequency of alcohol use and heavy drinking, sexual distress, and sex-related drinking motives, and sexual revictimization. participants will engage in both individual and group based intervention for alcohol use, sexual distress, and sexual assault risk. follow-up assessments are completed at 2- and 6-months following program completion. the intervention will be compared to a general health promotion control group.


Eligibility criteria:
inclusion criteria: 1. be between the ages of 18 and 24; 2. speak and comprehend english; 3. report a history of attempted or completed penetrative acts of sexual victimization (i.e., oral, vaginal, anal) since age 14 via incapacitation or force; 4. report exceeding the national recommended limits for daily drinking (4 or more for women) on two or more occasions in the past month; 5. report past month sexual activity; 6. exceed the clinical cut point on the female sexual functioning index. exclusion criteria: 1. suicide risk on the beck depression inventory; 2. screen positive on the alcohol use withdrawal checklist.
clinical trial to optimise levels of vitamin d for rhinovirus protection

Conditions: Common Cold

Summary: a phase ii randomised, placebo-controlled trial to identify the optimal regimen of vitamin d supplementation for rhinovirus protection, determined by host responses to a clinically induced rhinovirus challenge. the primary outcome is rhinovirus titre after inoculation with rhinovirus; secondary outcomes are self-reported respiratory symptom scores, concentrations of cytokines and chemokines sampled from the nasal mucosa, and the transcriptional responses of nasal epithelial cells.


Eligibility criteria:
inclusion criteria: 1. age 18-70 years 2. gives written informed consent 3. serum 25-hydroxyvitamin d concentration \<75 nmol/l 4. agrees not to take supplement containing vitamin d during participation 5. agrees not to commence smoking or vaping during participation exclusion criteria: 1. current smoker or vaper 2. taken vitamin d supplement or other supplement containing vitamin d, in previous 3 months 3. sunny holiday abroadi, defined as any location 51 degrees north/south of the equator, for ≥1 week, in the previous 3 months 4. dependent(s) \<6 months old 5. positive serology for anti-rv16 antibodies 6. living with someone with severe airways disease 7. any of the following medical conditions: 1. diabetes mellitus 2. asthma 3. chronic obstructive pulmonary disease 4. respiratory allergies 5. sarcoidosis 6. hyperparathyroidism 7. nephrolithiasis 8. active tuberculosis 9. liver failure 10. renal failure 11. lymphoma or other malignancy not in remission for ≥ 3 years

Keywords: rhinovirus
environmental factor and onset of spontaneous pneumothorax

Conditions: Spontaneous Pneumothorax

Summary: the study aims to evaluate the association between spontaneous pneumothorax onset and weather parameters.

the aim of this study is to analyse the relation between onset of the psp and exposure to environmental factors such as atmospheric pressure. a case-crossover epidemiological study will be conducted in 14 french hospitals. sp recorded from 2009 to 2013 will be exhaustively included. demographic and clinical characteristics will be collected. for each incident case of sp, the period of occurrence of the event (case period) will be compared to several other periods temporally distant from the case period (control periods prior to and after the event). exposure will be assessed using meteorological stations localized in the vicinity of each patient's home. a potential threshold effect and/or time lag effect between exposure and admission for sp will be explored. the results of this study will help to identify the meteorological factors associated with the occurrence of sp, and to deepen our knowledge of the pathophysiological mechanisms of sp especially the influence of meteorological factors on bleb rupture.

Eligibility criteria:
inclusion criteria: * age over 18 years * first episode of primary spontaneous pneumothorax exclusion criteria: * patients with traumatic * patients with secondary pneumothorax * patients with recurrent pneumothorax and patients with short-term readmissions (recurrence was defined as a new ed admission for the same diagnosis more than 14 days after the first admission).

Keywords: environment pressure temperature case-crossover
comparison of lidocaine-prilocaine combination and vapocoolant for iv cannulation pain in the ed

Conditions: Pain

Summary: hypothesis: lidocaine-prilocaine combination is as effective as vapocoolant in treating iv cannulation pain in the emergency department.

lidocain-prilocaine combination cream is two amide-type local anesthetics used for topical skin anesthesia. vapocoolant spray is also another method for providing appropriate analgesia through crayoanesthetic mechanisms. although there are some contraindications and adverse effects, these are widely used in the emergency department (ed) for iv cannulation pain.

Eligibility criteria:
inclusion criteria: * low acute patients who are waiting for the admission to the ed and require iv cannulation exclusion criteria: * altered mental status * uncooperative patients * unable to communicate * known history of hypersensitivity reaction to cold or amid analgesics * analgesic usage in previous 6 hours * no consent * emergent condition * pregnancy and lactation